These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 36927803)
1. Efficient tumor synergistic chemoimmunotherapy by self-augmented ROS-responsive immunomodulatory polymeric nanodrug. Song J; Cheng M; Xie Y; Li K; Zang X J Nanobiotechnology; 2023 Mar; 21(1):93. PubMed ID: 36927803 [TBL] [Abstract][Full Text] [Related]
2. Photodynamic PEG-coated ROS-sensitive prodrug nanoassemblies for core-shell synergistic chemo-photodynamic therapy. Sun B; Chen Y; Yu H; Wang C; Zhang X; Zhao H; Chen Q; He Z; Luo C; Sun J Acta Biomater; 2019 Jul; 92():219-228. PubMed ID: 31078764 [TBL] [Abstract][Full Text] [Related]
3. A polymeric IDO inhibitor based on poly(ethylene glycol)- Liu Y; Xie J; Zhao X; Zhang Y; Zhong Z; Deng C Biomater Sci; 2022 Sep; 10(19):5731-5743. PubMed ID: 36039890 [TBL] [Abstract][Full Text] [Related]
4. A Self-amplifying ROS-sensitive prodrug-based nanodecoy for circumventing immune resistance in chemotherapy-sensitized immunotherapy. Zhang J; Sun X; Xu M; Zhao X; Yang C; Li K; Zhao F; Hu H; Qiao M; Chen D; Zhao X Acta Biomater; 2022 Sep; 149():307-320. PubMed ID: 35764242 [TBL] [Abstract][Full Text] [Related]
5. Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy. Wan Z; Sun J; Xu J; Moharil P; Chen J; Xu J; Zhu J; Li J; Huang Y; Xu P; Ma X; Xie W; Lu B; Li S Acta Biomater; 2019 May; 90():300-313. PubMed ID: 30930305 [TBL] [Abstract][Full Text] [Related]
6. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer. Zang X; Song J; Yi X; Piyu J J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372 [TBL] [Abstract][Full Text] [Related]
8. Cinnamaldehyde-based poly(thioacetal): A ROS-awakened self-amplifying degradable polymer for enhanced cancer immunotherapy. Tu Y; Xiao X; Dong Y; Li J; Liu Y; Zong Q; Yuan Y Biomaterials; 2022 Oct; 289():121795. PubMed ID: 36108580 [TBL] [Abstract][Full Text] [Related]
9. Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy. Shi M; Zhang J; Wang Y; Han Y; Zhao X; Hu H; Qiao M; Chen D Acta Biomater; 2022 Sep; 150():353-366. PubMed ID: 35843594 [TBL] [Abstract][Full Text] [Related]
10. A Triple-Responsive Polymeric Prodrug Nanoplatform with Extracellular ROS Consumption and Intracellular H Li Y; Cao Y; Ma K; Ma R; Zhang M; Guo Y; Song H; Sun N; Zhang Z; Yang W Adv Healthc Mater; 2024 Jun; 13(16):e2303568. PubMed ID: 38319010 [TBL] [Abstract][Full Text] [Related]
11. A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy. Ding M; Fan Y; Lv Y; Liu J; Yu N; Kong D; Sun H; Li J Acta Biomater; 2022 Sep; 149():334-346. PubMed ID: 35779775 [TBL] [Abstract][Full Text] [Related]
12. Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway. Liu D; Chen B; Mo Y; Wang Z; Qi T; Zhang Q; Wang Y Nano Lett; 2019 Oct; 19(10):6964-6976. PubMed ID: 31518149 [TBL] [Abstract][Full Text] [Related]
13. Transformable prodrug nanoplatform Yang W; Yi J; Zhu R; Guo Y; Zhang K; Cao Y; Li X; Zhang J; Zhang Z; Li Y; Chen X Theranostics; 2023; 13(6):1906-1920. PubMed ID: 37064869 [No Abstract] [Full Text] [Related]
14. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes. Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390 [TBL] [Abstract][Full Text] [Related]
15. Efficient TNBC immunotherapy by dual reprogramming tumor-infiltrating dendritic cells and tumor-associated macrophages with stimulus-responsive miR155 nanocomplexes. Jing Z; Li Y; Song J; Zang X Int J Biol Macromol; 2023 Dec; 253(Pt 3):126912. PubMed ID: 37722648 [TBL] [Abstract][Full Text] [Related]
16. A Self-Amplifying ROS-Responsive Nanoplatform for Simultaneous Cuproptosis and Cancer Immunotherapy. Wu H; Zhang Z; Cao Y; Hu Y; Li Y; Zhang L; Cao X; Wen H; Zhang Y; Lv H; Jin X Adv Sci (Weinh); 2024 Jun; 11(23):e2401047. PubMed ID: 38569217 [TBL] [Abstract][Full Text] [Related]
17. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy. Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476 [TBL] [Abstract][Full Text] [Related]
18. Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo. Chuan X; Song Q; Lin J; Chen X; Zhang H; Dai W; He B; Wang X; Zhang Q Mol Pharm; 2014 Oct; 11(10):3656-70. PubMed ID: 25208098 [TBL] [Abstract][Full Text] [Related]
19. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer. He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524 [TBL] [Abstract][Full Text] [Related]
20. Codelivery of Anti-PD-1 Antibody and Paclitaxel with Matrix Metalloproteinase and pH Dual-Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy. Su Z; Xiao Z; Wang Y; Huang J; An Y; Wang X; Shuai X Small; 2020 Feb; 16(7):e1906832. PubMed ID: 31990457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]